| scholarly article | Q13442814 |
| review article | Q7318358 |
| P819 | ADS bibcode | 2013PLoSO...859551B |
| P356 | DOI | 10.1371/JOURNAL.PONE.0059551 |
| P932 | PMC publication ID | 3608726 |
| P698 | PubMed publication ID | 23555704 |
| P5875 | ResearchGate publication ID | 236106557 |
| P50 | author | Ingram Olkin | Q6033052 |
| Mark Holodniy | Q37367057 | ||
| Douglas K Owens | Q98149051 | ||
| Richard Olshen | Q102117245 | ||
| P2093 | author name string | Manisha Desai | |
| Eran Bendavid | |||
| Vandana Sundaram | |||
| Nanjiang Hou | |||
| Katherine Niehaus | |||
| Clay Bavinger | |||
| Nicole Wein | |||
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews | Q29547775 | ||
| Marginal structural models and causal inference in epidemiology | Q29619287 | ||
| Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration | Q30993245 | ||
| Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? | Q33184007 | ||
| Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study | Q33521080 | ||
| Invited commentary: propensity scores | Q33715877 | ||
| No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis | Q34296639 | ||
| No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. | Q34708243 | ||
| Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies | Q35169664 | ||
| Performance of propensity score calibration--a simulation study. | Q35933863 | ||
| Cardiovascular risk and body-fat abnormalities in HIV-infected adults | Q36000980 | ||
| Instruments for causal inference: an epidemiologist's dream? | Q36498027 | ||
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients | Q37102523 | ||
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration | Q37208045 | ||
| Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors | Q37457737 | ||
| Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons | Q37542914 | ||
| Methodological concerns and quality appraisal of contemporary systematic reviews and meta-analyses in pediatric urology | Q37877888 | ||
| Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis | Q37993138 | ||
| Risk factors for myocardial infarction in HIV-positive patients | Q39375472 | ||
| Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. | Q42957305 | ||
| Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites | Q43117361 | ||
| Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial | Q43258269 | ||
| Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study | Q43291742 | ||
| Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. | Q44268615 | ||
| Combination antiretroviral therapy and the risk of myocardial infarction | Q44662157 | ||
| Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures | Q45306426 | ||
| Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection | Q45729086 | ||
| Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. | Q45734592 | ||
| Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects | Q46090282 | ||
| Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort | Q46392559 | ||
| Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. | Q48856213 | ||
| An open-label, prospective, observational study of the incidence of coronary artery disease in patients with hiv infection receiving highly active antiretroviral therapy | Q50733305 | ||
| Cardio- and cerebrovascular events in HIV-infected persons. | Q53286263 | ||
| Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. | Q53922664 | ||
| Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use | Q56830806 | ||
| Class of Antiretroviral Drugs and the Risk of Myocardial Infarction | Q57181081 | ||
| Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients | Q57955505 | ||
| Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study | Q74223056 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | public domain | Q19652 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| systematic review | Q1504425 | ||
| anti-HIV agents | Q50377208 | ||
| anti-retroviral agent | Q50430310 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e59551 | |
| P577 | publication date | 2013-03-26 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review | |
| P478 | volume | 8 |
| Q89293222 | A Systematic Review of Cardiovascular Disease in Sexual Minorities |
| Q41996857 | A review of drug-drug interactions in older HIV-infected patients |
| Q55001110 | Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials. |
| Q58055043 | Abstracts of the HIV Drug Therapy in the Americas 8-10 May 2014, Rio de Janeiro, Brazil |
| Q38490362 | Ageing with HIV: a multidisciplinary review. |
| Q59353208 | An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients |
| Q90322416 | Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014-2017 BRFSS |
| Q40229714 | Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients |
| Q42238390 | Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals. |
| Q28080289 | Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review |
| Q55512944 | Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015. |
| Q57180790 | British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 |
| Q47107432 | Cardiovascular Disease and Cardiovascular Disease Risk in HIV-Positive Populations in the Asian Region |
| Q51779710 | Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection. |
| Q38950123 | Cardiovascular Risk in HIV-Infected and Uninfected Postmenopausal Minority Women: Use of the Framingham Risk Score |
| Q37661603 | Cardiovascular disease and HIV infection |
| Q38876754 | Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report. |
| Q39165028 | Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer |
| Q35102751 | Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study |
| Q30364312 | Developments in HIV-1 immunotherapy and therapeutic vaccination. |
| Q28543075 | Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray study |
| Q26768591 | Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients |
| Q38996992 | Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority tri |
| Q92354047 | Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects |
| Q36156655 | Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012. |
| Q41736369 | Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study |
| Q33998067 | Epidemiology of coronary heart disease in patients with human immunodeficiency virus |
| Q39008634 | Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. |
| Q64086650 | Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004-2015 |
| Q37141511 | Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserve |
| Q58159945 | Flexible Marginal Structural Models for Estimating the Cumulative Effect of a Time-Dependent Treatment on the Hazard: Reassessing the Cardiovascular Risks of Didanosine Treatment in the Swiss HIV Cohort Study |
| Q64446869 | Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV |
| Q36071230 | HIV Infection Is Not Associated with Carotid Intima-Media Thickness in Brazil: A Cross-Sectional Analysis from the INI/ELSA-Brasil Study |
| Q26827746 | HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research |
| Q64103636 | HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study |
| Q27008915 | HIV infection and cardiovascular disease |
| Q33896762 | HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems |
| Q64911219 | HIV-associated cardiovascular disease: importance of platelet activation and cardiac fibrosis in the setting of specific antiretroviral therapies. |
| Q59806016 | Hypertension Risk with Abacavir Use among HIV-Infected Individuals: A Nationwide Cohort Study |
| Q41738666 | Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. |
| Q34034101 | Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection |
| Q37076185 | Inflammatory Markers Associated With Subclinical Coronary Artery Disease: The Multicenter AIDS Cohort Study. |
| Q33649200 | Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? |
| Q35977313 | Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration |
| Q36311127 | Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. |
| Q34656807 | Learning lessons from operational research in infectious diseases: can the same model be used for noncommunicable diseases in developing countries? |
| Q89839796 | Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV |
| Q43986551 | Measuring food and nutrition security: tools and considerations for use among people living with HIV. |
| Q37418053 | Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects |
| Q51777203 | Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. |
| Q41505058 | Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life |
| Q39124502 | Population-level decline in BMI and systolic blood pressure following mass HIV treatment: Evidence from rural KwaZulu-Natal |
| Q59808441 | Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: a validation study at a single center |
| Q33629178 | Premature Coronary Artery Disease and ST-Elevation Myocardial Infarction in a 24-Year-Old Man With Perinatally Acquired Human Immunodeficiency Virus: A Case Report |
| Q47602080 | Prevalence and Correlates of Smoking Among People Living With HIV in South Africa |
| Q89937334 | Prevalence of Non-AIDS Comorbidities and Factors Associated with Metabolic Complications among HIV-Infected Patients at a Thai Referral Hospital |
| Q89515566 | Prevention of stroke in people living with HIV |
| Q38168587 | Raltegravir as antiretroviral therapy in HIV/AIDS. |
| Q40422802 | Relationship Between HIV Infection, Antiretroviral Therapy, Inflammatory Markers, and Cerebrovascular Endothelial Function Among Adults in Urban China. |
| Q56243525 | Risk of Cardiovascular Disease Associated With Exposure To Abacavir Among Individuals With HIV: A Systematic Review And Meta-analyses Of Results From Seventeen Epidemiologic Studies |
| Q36899983 | Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens |
| Q36137160 | Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study |
| Q36693929 | Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population |
| Q42609996 | Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. |
| Q90261273 | Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis |
| Q26765518 | Role of endoplasmic reticulum stress in drug-induced toxicity |
| Q37418140 | Serious Non-AIDS events: Immunopathogenesis and interventional strategies |
| Q33851741 | Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa |
| Q55440437 | Sexual Orientation Differences in Modifiable Risk Factors for Cardiovascular Disease and Cardiovascular Disease Diagnoses in Men. |
| Q92071364 | Stroke in HIV |
| Q39262004 | Survival Benefit of Kidney Transplantation in HIV-infected Patients |
| Q28553066 | Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice |
| Q26765200 | The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds |
| Q57166290 | The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro |
| Q59806829 | The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality |
| Q45783074 | The Role of Transforming Growth Factor Beta-1 in the Progression of HIV/AIDS and Development of Non-AIDS-Defining Fibrotic Disorders |
| Q36389888 | The association between alcohol use and cardiovascular disease among people living with HIV: a systematic review |
| Q42400573 | The efficiency of chronic disease care in sub-Saharan Africa |
| Q36098224 | Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study |
| Q35097454 | Traditional risk factors are more relevant than HIV-specific ones for carotid intima-media thickness (cIMT) in a Brazilian cohort of HIV-infected patients |
| Q91703785 | Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA® Observational Database |
| Q38900051 | Update on Pediatric Human Immunodeficiency Virus Infection: Paradigms in Treatment and Prevention |
| Q37049808 | Urinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy |
Search more.